Aratana Therapeutics (Aratana Therapeutics) Cash-to-Debt : 46.55 (As of Mar. 2019)

View and export this data going back to 2013. Start your Free Trial

What is Aratana Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Aratana Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2019 was 46.55.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Aratana Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2019.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Aratana Therapeutics's Cash-to-Debt or its related term are showing as below:

PETX's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.575
* Ranked among companies with meaningful Cash-to-Debt only.

Aratana Therapeutics Cash-to-Debt Historical Data

The historical data trend for Aratana Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Aratana Therapeutics Cash-to-Debt Chart

Aratana Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Cash-to-Debt

Get a 7-Day Free Trial

6.55

2.17

2.20

1.84

No Debt

Aratana Therapeutics Quarterly Data
	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19
Cash-to-Debt	Get a 7-Day Free Trial															1.97	2.03	2.22	No Debt	46.55

Competitive Comparison of Aratana Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Aratana Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aratana Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aratana Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Aratana Therapeutics's Cash-to-Debt falls into.

Aratana Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Aratana Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2018 is calculated as:

Aratana Therapeutics had no debt ⁽¹⁾.

Aratana Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2019 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	37.057	/	(0.398	+	0.398)
	=	46.55

Aratana Therapeutics (NAS:PETX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Aratana Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Aratana Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Aratana Therapeutics (Aratana Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aratana Therapeutics Inc (NAS:PETX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

11400 Tomahawk Creek Parkway, Suite 340, Leawood, KS, USA, 66211

Website

http://www.aratana.com

Aratana Therapeutics Inc is a pet therapeutics company. Its main activity is the licensing, developing, and commercializing of innovative biopharmaceutical products for companion animals. The company's portfolio consists of therapeutic candidates such as small-molecule pharmaceuticals and large-molecule biologics. The main product candidates in development comprise small-molecule pharmaceuticals directed at treating osteoarthritis pain, inflammation, appetite stimulation, and post-operative pain. The firm's strategy consists of licensing proprietary technology from human biopharmaceutical companies or academia to develop therapeutics specifically for use in pets.

Executives

Roche Robert P Jr	director	41 MOORES ROAD FRAZER PA 19355
Vort John Vander	director	C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Lowell W Robinson	director	470 WEST END AVENUE, NEW YORK NY 10024
Wendy L Yarno	director
David L Brinkley	director	901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Merilee Raines	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Craig A. Barbarosh	director	3525 PIEDMONT RD., NE, BUILDING 6, SUITE 700, ATLANTA GA 30305
Hockaday Irvine O Jr	director	SPRINT NEXTEL CORPORATION, 2001 EDMUND HALLEY DRIVE, RESTON VA 20191
Craig A Tooman	director, officer: President and CEO
Peter Steven St	director, officer: PRESIDENT AND CEO	MPM CAPITAL, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Laura Brege	director	C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Jay Lichter	director	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211